Mountain View Pharmaceuticals, Inc. Announces Receipt of a U.S. Patent on Next-Generation PEGylation Technology (PharmaPEG)

Published: Mar 14, 2012

MENLO PARK, Calif.--(BUSINESS WIRE)--Mountain View Pharmaceuticals, Inc. (“MVP”) announced today its receipt of U.S. Patent No. 8,129,330 B2 titled “Polymer Conjugates with Decreased Antigenicity, Methods of Preparation and Uses Thereof.

Back to news